This article first appeared on GuruFocus .
Release Date: June 30, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Tecsys Inc ( TCYSF ) reported record Q4 revenue of $50 million and record full-year revenue of $193 million.
-
SaaS revenue grew by 20% for the year, with adjusted EBITDA reaching 10% ahead of guidance.
-
The company added significant new customers, including Memorial Hermann Health System and Shepherd Center, enhancing its healthcare solutions portfolio.
-
New logo bookings increased by 33% year-over-year, indicating strong demand and a robust pipeline.
-
Tecsys Inc ( TCYSF ) was recognized as a leader in the 2025 Nucleus Research WMS Technology Value Matrix and included in the 2026 Gartner Magic Quadrant for Warehouse Management Systems.
Negative Points
-
The company reported a net loss of $0.2 million in Q4 fiscal 2026, compared to a net profit of $1.7 million in the same quarter last year.
-
There was a $3.4 million after-tax restructuring cost impacting the net loss.
-
Maintenance and support revenue is expected to decline, impacting overall revenue growth.
-
SaaS migration bookings saw a significant decline, indicating a slowdown in converting legacy systems to SaaS.
-
The company anticipates ongoing declines in legacy maintenance revenue, which could affect future revenue streams.
Q & A Highlights
Q: Can you clarify the expected decline in maintenance and support revenue and how SaaS conversions are impacting this? A: Mark Bentler, CFO: We anticipate a decline in maintenance and support revenue, but not as steep as 20%. This decline is primarily due to the tail end of SaaS migrations. SaaS migration bookings have significantly decreased, and we expect this trend to continue at a lower level, with a long tail of conversions remaining.
Q: With the expected SaaS growth, will most of it come from new customers and expansions rather than migrations? A: Mark Bentler, CFO: Yes, the majority of SaaS growth will come from new customers and expansions. The impact of migrations will be much less significant going forward.
Q: How do you see the U.S. healthcare market demand and sales cycles progressing? A: Peter Burton, CEO: Demand remains strong with an active pipeline. Despite concerns about reimbursements and coverage, hospitals are focusing on finding efficiencies, which benefits us. Our platform can save significant costs, and the momentum is strong, as evidenced by our successful user conference.
Q: What are the assumptions behind the full-year SaaS growth guidance of 13% to 15%? A: Peter Burton, CEO: The growth is driven by new accounts and expansions, with minimal churn on our Elite platform. The legacy product is declining, which affects the overall SaaS growth number, but Elite SaaS growth remains close to 20%.
Q: Is M&A a priority for capital allocation in the near to mid-term? A: Peter Burton, CEO: We don't see much M&A activity in the near term due to the current market dynamics. Our shares are likely the best option for capital allocation. We may consider small acquisitions that strengthen our position in healthcare, but they would not be significant.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
